← Back to Screener
OmniAb, Inc. Common Stock (OABI)
Price$1.56
Favorite Metrics
Price vs S&P 500 (26W)-19.41%
Price vs S&P 500 (4W)-24.50%
Market Capitalization$214.28M
All Metrics
Book Value / Share (Quarterly)$1.85
P/TBV (Annual)1.88x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-31.89%
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)-22.64%
Net Profit Margin (TTM)-347.04%
EPS (TTM)$-0.58
10-Day Avg Trading Volume0.49M
EPS Excl Extra (TTM)$-0.58
Revenue Growth (5Y)-4.31%
EPS (Annual)$-0.57
ROI (Annual)-24.26%
Gross Margin (Annual)98.38%
Net Profit Margin (5Y Avg)-169.17%
Cash / Share (Quarterly)$0.37
Revenue Growth QoQ (YoY)-22.47%
ROA (Last FY)-21.53%
Revenue Growth TTM (YoY)-29.27%
EBITD / Share (TTM)$-0.49
ROE (5Y Avg)-16.00%
Operating Margin (TTM)-369.49%
Cash Flow / Share (Annual)$-0.26
P/B Ratio0.80x
P/B Ratio (Quarterly)1.00x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)10.11x
Net Interest Coverage (TTM)-3434.00x
ROA (TTM)-21.37%
EPS Incl Extra (Annual)$-0.57
Current Ratio (Annual)4.02x
Quick Ratio (Quarterly)3.85x
3-Month Avg Trading Volume0.42M
52-Week Price Return-23.32%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.98
P/S Ratio (Annual)11.48x
Asset Turnover (Annual)0.06x
52-Week High$2.29
Operating Margin (5Y Avg)-200.51%
EPS Excl Extra (Annual)$-0.57
CapEx CAGR (5Y)-20.24%
26-Week Price Return-15.43%
Quick Ratio (Annual)3.85x
13-Week Price Return-22.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.02x
Enterprise Value$188.754
Revenue / Share Growth (5Y)-4.06%
Asset Turnover (TTM)0.06x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-355.16%
Cash / Share (Annual)$0.37
3-Month Return Std Dev47.21%
Net Income / Employee (TTM)$-1
ROE (Last FY)-24.26%
EPS Basic Excl Extra (Annual)$-0.57
Receivables Turnover (TTM)2.95x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.58
Receivables Turnover (Annual)2.95x
ROI (TTM)-23.99%
P/S Ratio (TTM)11.48x
Pretax Margin (5Y Avg)-191.42%
Revenue / Share (Annual)$0.16
Tangible BV / Share (Annual)$0.98
Price vs S&P 500 (52W)-53.15%
Year-to-Date Return-20.00%
5-Day Price Return-1.33%
EPS Normalized (Annual)$-0.57
ROA (5Y Avg)-13.65%
Net Profit Margin (Annual)-347.04%
Month-to-Date Return-5.73%
Cash Flow / Share (TTM)$-0.10
EBITD / Share (Annual)$-0.49
Operating Margin (Annual)-369.49%
ROI (5Y Avg)-16.00%
EPS Basic Excl Extra (TTM)$-0.58
P/TBV (Quarterly)1.88x
P/B Ratio (Annual)1.00x
Pretax Margin (TTM)-355.16%
Book Value / Share (Annual)$1.85
Price vs S&P 500 (13W)-23.20%
Beta0.14x
P/FCF (Annual)304.81x
Revenue / Share (TTM)$0.15
ROE (TTM)-23.99%
52-Week Low$1.22
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.23
4.23
4.23
4.23
Industry Peers — R&D — Physical Sciences(9)
| Symbol | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|
OABIOmniAb, Inc. Common Stock | — | -23.99% | -4.31% | — | $1.56 |
IQVIQVIA Holdings Inc. | 22.22x | 22.28% | 7.50% | — | $171.95 |
INCYIncyte Genomics Inc | 14.67x | 29.15% | 14.03% | — | $95.32 |
MEDPMedpace Holdings, Inc. Common Stock | 32.83x | 118.82% | 22.27% | — | $515.65 |
CRLCharles River Laboratories International, Inc. | — | -4.40% | 6.55% | — | $176.94 |
ABSIAbsci Corporation Common Stock | — | -59.68% | -10.14% | — | $3.23 |
NRCNational Research Corporation Common Stock (Delaware) | 34.98x | 58.51% | 0.61% | 3.59% | $17.62 |
MXCTMaxCyte, Inc. Common Stock | — | -24.06% | 4.76% | — | $0.82 |
NOTVInotiv, Inc. Common Stock | — | -50.77% | 53.35% | — | $0.30 |
ISPCiSpecimen Inc. Common Stock | — | -496.37% | -25.09% | — | $0.12 |
About
OmniAb licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses engineered transgenic animals powered by proprietary Biological Intelligence to rapidly identify optimized antibody candidates for drug development. The company generates revenue through licensing agreements that accelerate its partners' therapeutic discovery efforts.